Acumen Pharmaceuticals, Inc. (ABOS)
0.2432
+0.02
(+8.81%)
USD |
NASDAQ |
Nov 09, 11:58
Acumen Pharmaceuticals Enterprise Value : -36.13M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -36.13M |
| November 05, 2026 | -36.83M |
| November 04, 2026 | -36.65M |
| November 03, 2026 | -35.34M |
| November 02, 2026 | -34.96M |
| October 30, 2026 | -37.10M |
| October 29, 2026 | 113.34M |
| October 28, 2026 | 119.85M |
| October 27, 2026 | 111.17M |
| October 26, 2026 | 111.89M |
| October 23, 2026 | 90.92M |
| October 22, 2026 | 96.70M |
| October 21, 2026 | 94.53M |
| October 20, 2026 | 93.45M |
| October 19, 2026 | 75.73M |
| October 16, 2026 | 69.94M |
| October 15, 2026 | 68.49M |
| October 14, 2026 | 73.92M |
| October 13, 2026 | 78.98M |
| October 12, 2026 | 93.81M |
| October 09, 2026 | 102.49M |
| October 08, 2026 | 99.59M |
| October 07, 2026 | 99.59M |
| October 06, 2026 | 94.53M |
| October 05, 2026 | 101.76M |
| Date | Value |
|---|---|
| October 02, 2026 | 95.25M |
| October 01, 2026 | 97.42M |
| September 30, 2026 | 108.27M |
| September 29, 2026 | 83.80M |
| September 28, 2026 | 87.77M |
| September 25, 2026 | 83.43M |
| September 24, 2026 | 83.07M |
| September 23, 2026 | 88.13M |
| September 22, 2026 | 113.08M |
| September 21, 2026 | 108.74M |
| September 18, 2026 | 113.08M |
| September 17, 2026 | 107.30M |
| September 16, 2026 | 110.19M |
| September 15, 2026 | 130.44M |
| September 14, 2026 | 123.21M |
| September 11, 2026 | 132.61M |
| September 10, 2026 | 128.27M |
| September 09, 2026 | 127.55M |
| September 08, 2026 | 149.96M |
| September 04, 2026 | 151.41M |
| September 03, 2026 | 144.90M |
| September 02, 2026 | 145.62M |
| September 01, 2026 | 132.61M |
| August 31, 2026 | 127.55M |
| August 28, 2026 | 132.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 2.710B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.37M |
| Total Expenses (Quarterly) | 25.37M |
| EPS Diluted (Quarterly) | -0.3508 |
| Earnings Yield | -635.9% |
| Normalized Earnings Yield | -639.19 |